EP2905030

E R SQUIBB & SONS
Application Number
EP15156647A
Filing Date
Aug 11, 2009
Status
Granted And Under Opposition
Oct 4, 2019
Grant Date
Nov 6, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2905030B1 was granted on Nov 6, 2019 by E R Squibb & Sons The patent is currently Granted And Under Opposition.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

REGENERON PHARMACEUTICALSAug 5, 2020ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionUS6808710
N/A
OppositionWO2006121168
N/A
OppositionWO0243478
N/A
OppositionUS2006083744
N/A
OppositionWO9530750
N/A
OppositionUS6197524
N/A
OppositionEP0758383
N/A
OppositionUS5874250
N/A
OppositionUS5976877
N/A
OppositionWO2010019570
N/A
OppositionUS10358495
N/A

Access Full Citation Information

Get a free, in-depth citation report including examiner, opposition, and international search citations.

Get Free Citation Report

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.